.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB02_Imiglucerase.Imiglucerase

Information

Imiglucerase is a recombinant enzyme replacement therapy used for the treatment of Gaucher disease type 1, a rare genetic lysosomal storage disorder. It is a modified form of the human enzyme β-glucocerebrosidase, and it helps reduce the accumulation of glucocerebroside in macrophages. Imiglucerase is approved and widely used as a standard care for Gaucher disease type 1.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with type 1 Gaucher disease following intravenous infusion. Data represent average PK values from published studies.

References

1. Berger, J, et al., & Berger, MG (2019). Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1. Clinical pharmacokinetics 58(4) 469–482. DOI:10.1007/s40262-018-0708-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30128966

2. Morris, JL (2012). Velaglucerase alfa for the management of type 1 Gaucher disease. Clinical therapeutics 34(2) 259–271. DOI:10.1016/j.clinthera.2011.12.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22264444

3. Sekijima, Y, et al., & Fukushima, Y (2010). Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clinical therapeutics 32(12) 2048–2052. DOI:10.1016/j.clinthera.2010.11.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21118740

Revisions

• 06/2025 initial generated model